☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 85-3911080 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
222 Jacobs Street, Suite 200 Cambridge, MA | 02141 | |
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common stock, par value $0.0001 per share | CERE | The NASDAQ Stock Market LLC |
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
PART IV
Item 15. Exhibit and Financial Statement Schedules.
(a)(1) For a list of the financial statements, see Index to the Financial Statements on page F-1 of the Original Form 10-K.
(2) Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.
(3) Exhibits
The exhibits required by Item 601 of Regulation S-K and Item 15(b) are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.
(b) Exhibit Index
* Filed or furnished with the Original Form 10-K.
(1) | Filed or furnished herewith. |
# | Indicates a management contract, compensatory plan or arrangement. |
† | Schedules, exhibits or similar attachments to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule, exhibit or similar attachment to the SEC upon request. |
†† | Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit. |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
CEREVEL THERAPEUTICS HOLDINGS, INC. | ||||||
Date: May 19, 2023 | By: | /s/ N. Anthony Coles | ||||
N. Anthony Coles | ||||||
Chief Executive Officer |